CAS: 289905-88-0; 1-((2-Chlorophenyl)Diphenylmethyl)-1H-Pyrazole

该化合物是一种化学化合物,其特点是其颗粒核心,由五人组成,内含两个相邻氮原子的环,该化合物具有2-氯联苯组和二苯甲基组,有助于其独特的结构和电子特性;苯环上存在氯原子,会影响化合物的再活性和溶性,而二苯甲基混合物会增加其成份.一般情况下,这种化合物可能展示生物活动,使其对药用化学和药物开发具有兴趣;总体分子结构表明与生物目标可能发生相互作用,可能导致各种药用效应;此外,该化合物的稳定性,有机溶解性以及形成氢联结的潜力是影响其在化学反应和应用中行为的重要特征.与许多有机化合物一样,由于潜在的毒性或再活性,应观测安全性和处理预防措施.

结构式图片

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-8067460-B2
    优先权日:2004-10-04
    标 题 :5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
    发明人:WULFF HEIKE; SANKARANARAYANAN ANANTHAKRISHNAN; HAENSEL WOLFRAM; SCHMITZ ALEXANDER; SCHMIDT-LASSEN KRISTINA
    权利人:WULFF HEIKE; SANKARANARAYANAN ANANTHAKRISHNAN; HAENSEL WOLFRAM; SCHMITZ ALEXANDER; SCHMIDT-LASSEN KRISTINA; UNIV CALIFONIA
    摘要:Compositions of matter comprising 5-phenoxyalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or animal subjects, including autoimmune diseases. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition. In some embodiments, the compounds are more selective for certain potassium channels (e.g., Kv1.3 channels) than other potassium channels (e.g., Kv1.5 channels).

    专利号:US-2024342119-A1
    优先权日:2021-08-02
    标 题:Composition for treating hypertrophic scars and keloids comprising benzhydryl thioacetamide compound as active ingredient
    发明人:KIM SEONG-JIN; KIM SEON-MYUNG
    权利人:CELLIONBIOMED INC
    摘要:The present invention relates to a composition for treating hypertrophic scars and keloids, comprising a benzhydryl thioacetamide compound as an active ingredient. The benzhydryl thioacetamide compound inhibits cell proliferation and an increase in intracellular Ca 2+ concentration, in fibroblasts, keratinocytes and vascular endothelial cells that are involved in skin fibrosis, and inhibits the synthesis of collagen, which is the extracellular matrix, and thus has the effect of effectively treating intractable hypertrophic scars and keloids.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Glaser N, Chu S, Weiner J, Zdepski L, Wulff H, Tancredi D, ODonnell ME. Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Res Care. 2022 May;10(3):e002777. doi: 10.1136/bmjdrc-2022-002777.
    2: Schilling T, Eder C. TRAM-34 inhibits nonselective cation channels. Pflugers Arch. 2007 Jul;454(4):559-63. doi: 10.1007/s00424-007-0232-4. Epub 2007 Feb 23. 19(18):3515-21. 37(12):995-1002. doi: 10.1093/ajh/hpae115.
    5: Stransky N, Ganser K, Quintanilla-Martinez L, Gonzalez-Menendez I, Naumann U, Eckert F, Koch P, Huber SM, Ruth P. Efficacy of combined tumor irradiation and KCa3.1-targeting with TRAM-34 in a syngeneic glioma mouse model. Sci Rep. 2023 Nov 23;13(1):20604. doi: 10.1038/s41598-023-47552-4.

    合成参考文献


    参考文献:10.1038/jcbfm.2011.101
    摘要:Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363–74.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知